NCT02471859View on ClinicalTrials.gov

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Healthy Volunteer

Interventions

DRUG

GDC-3280

GDC-3280 at various doses, depending on the cohort and treatment period

DRUG

Placebo

Placebo at various doses, depending on the cohort and treatment period

Trial Locations (1)

LS2 9LH

Leeds

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY